Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Total Articles

1
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (0)

Searched Name

Cancer différencié de la thyroïde

Ranked By

Impact Index Per Article
Citation(s) in RCA

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Today ()
Yesterday ()
This Week ()
Last Week ()
Current Month ()
Last Month ()

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	[Drug approval: Cabozantinib monotherapy in advanced thyroid cancers refractory or not eligible for radioactive iodine treatment, after progression under previous systemic therapies]. Bull Cancer 2022;109:1103-1104. [PMID: 36220695 DOI: 10.1016/j.bulcan.2022.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 08/15/2022] [Indexed: 06/16/2023] Abstract Collapse Key Words Cancer différencié de la thyroïde Differentiated thyroid cancers Inhibiteurs thyrosine kinase Iode radioactif Multikinase inhibitors Radioiodine Targeted therapies Thérapies ciblées Collapse MESH Headings Humans Thyroid Neoplasms/drug therapy Thyroid Neoplasms/radiotherapy Iodine Radioisotopes/therapeutic use Drug Approval Anilides/therapeutic use Protein Kinase Inhibitors/therapeutic use Antineoplastic Agents/therapeutic use Collapse Grants Collapse

Number

Citation Analysis

[Drug approval: Cabozantinib monotherapy in advanced thyroid cancers refractory or not eligible for radioactive iodine treatment, after progression under previous systemic therapies]. Bull Cancer 2022;109:1103-1104. [PMID: 36220695 DOI: 10.1016/j.bulcan.2022.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 08/15/2022] [Indexed: 06/16/2023]